Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
SYN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.80%69.520.0%$2214.61m
NVAXNovavax, Inc. -16.77%124.4296.5%$1026.77m
SRNESorrento Therapeutics, Inc. -11.92%12.411.5%$731.21m
GILDGilead Sciences, Inc. 1.09%68.841.0%$571.41m
AMGNAmgen, Inc. 3.01%241.721.3%$485.13m
REGNRegeneron Pharmaceuticals, Inc. 2.25%612.352.7%$399.20m
VRTXVertex Pharmaceuticals, Inc. 3.43%270.851.9%$367.43m
BIIBBiogen, Inc. 1.13%293.221.6%$355.55m
BNTXBioNTech SE 0.96%69.110.0%$350.86m
ILMNIllumina, Inc. 0.86%344.143.5%$338.32m
VXRTVaxart, Inc. -14.42%9.200.0%$262.52m
ATNMActinium Pharmaceuticals, Inc. -0.31%9.6313.3%$232.11m
EBSEmergent BioSolutions, Inc. 6.00%129.676.4%$188.23m
ALXNAlexion Pharmaceuticals, Inc. 1.52%102.782.0%$167.84m
SGENSeattle Genetics, Inc. 3.46%158.796.0%$158.72m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.